Loading clinical trials...

An Observational Study to Validate the Cumulative Life Course Impairment (CLCI) Instrument (DermCLCI-p) in Adult Participants With Moderate to Severe Chronic Plaque Psoriasis (PsO) | Clinical Trials | Clareo Health

COMPLETED

An Observational Study to Validate the Cumulative Life Course Impairment (CLCI) Instrument (DermCLCI-p) in Adult Participants With Moderate to Severe Chronic Plaque Psoriasis (PsO)

Multi-Country Prospective Real-World Study to Validate the CLCI Instrument (DermCLCI-p) in Patients With Moderate-to-Severe Chronic Plaque Psoriasis (IMMagine)

NCT05959070•AbbVie

View on ClinicalTrials.gov

Summary

The IMMagine study aims to validate the newly developed CLCI instrument (DermCLCI-p) in moderate to severe psoriasis (PsO) patients, who will be started on Risankizumb (RZB) treatment and will be enrolled into the validation study up to 28 weeks. The treatment decision for RZB must be made independent of this study enrollment.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Confirmed diagnosis of moderate to severe chronic plaque-type psoriasis diagnosed by a dermatologist and presence of moderate to severe psoriasis symptoms according to physician's clinical judgment at the time of recruitment.
•Participants initiating RZB treatment for psoriasis as per local label. Physician's decision for treatment with risankizumab must have been reached prior to and independently of recruitment in the study.
•Participants able to understand and communicate with the investigator and comply with the requirements of the study.
•Willingness and ability to comply with all study requirements.

Exclusion Criteria

•\- Current or recent (within the last 30 days) participation in an interventional clinical trial.

Locations (16)

Universite Libre de Bruxelles - Hopital Erasme /ID# 252456

Anderlecht, Brussels Capital, Belgium

Cliniques Universitaires UCL Saint-Luc /ID# 253234

Brussels, Brussels Capital, Belgium

UZ Gent /ID# 252458

Ghent, Oost-Vlaanderen, Belgium

Dermatologie Maldegem /ID# 252454

Maldegem, Oost-Vlaanderen, Belgium

Universitair Ziekenhuis Leuven /ID# 252457

Leuven, Vlaams-Brabant, Belgium

Wiseman Dermatology Research /ID# 255883

Winnipeg, Manitoba, Canada

Dermatrials Research /ID# 253879

Hamilton, Ontario, Canada

Lynde Institute for Dermatology /ID# 253876

Markham, Ontario, Canada

JRB Research /ID# 253877

Ottawa, Ontario, Canada

SKiN Centre for Dermatology /ID# 255882

Peterborough, Ontario, Canada

Key Dates

Start Date

November 9, 2023

Primary Completion Date

March 21, 2025

Completion Date

March 21, 2025

Last Updated

May 2, 2025

Enrollment

154

ACTUAL participants

Conditions

Psoriasis

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

NCT07449234

Psoriasis

View study

RECRUITINGPHASE3

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967

Plaque Psoriasis

View study

RECRUITINGPHASE3

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

NCT07250802

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 2, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

An Observational Study to Validate the Cumulative Life Course Impairment (CLCI) Instrument (DermCLCI-p) in Adult Participants With Moderate to Severe Chronic Plaque Psoriasis (PsO)

Inclusion Criteria

Exclusion Criteria

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

Real-Life Evaluation of Guselkumab Dosing Interval Adjustments